Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

No significant differences were observed regarding sex, smoking status, total cholesterol, and 25-hydroxyvitamin D (all P > .05).

Source: 3.1. Baseline characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Rheumatoid arthritis was determined through self-reported responses based on an interview, with similar efficiency compared to clinical assessments confirmed by previous investigations.[,] Participants were first asked whether they had ever been diagnosed with any form of arthritis by a healthcare professional.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Sarcopenia, an independent predictor for all-cause mortality in rheumatoid arthritis: Insights from the NHANES database

Study design awaiting verification · Medicine · 2026

Original publication title

Sarcopenia, an independent predictor for all-cause mortality in rheumatoid arthritis: Insights from the NHANES database

Xiaodong Zhang; Hua Liu; Tianzuo Lan; Xin Cai

Copyright © 2026 the Author(s). Published by Wolters Kluwer Health, LLC.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The present longitudinal analysis identifies an association between sarcopenia and an elevated risk of all-cause mortality among patients with RA. This finding underscores the clinical relevance of monitoring skeletal muscle health in this population. Furthermore, the observed association provides a rationale for future research to evaluate the relationship between muscle status and long-term outcomes.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Rheumatoid arthritis (RA) is a systemic autoimmune disorder characterized by chronic inflammation that leads to progressive organ damage. Despite significant therapeutic advances over the past decades, including the widespread use of disease-modifying antirheumatic drugs and targeted therapies, patients with RA continue to face a significantly higher all-cause mortality than the general population.[1-3] This enduring mortality gap is quantified by standardized mortality ratios reported between 1.4 and 2.1 in large-scale cohort studies.[4-6]

Sarcopenia is defined by the Foundation for the National Institutes of Health (FNIH) Sarcopenia Project as the combination of low lean mass and muscle weakness associated with disability, frailty, and all-cause mortality.[7,8] Sarcopenia affects not only the elderly but also individuals with chronic inflammatory diseases, where systemic inflammation, metabolic disruption, and reduced physical activity contribute to muscle degradation.[9,10] Previous investigations indicate that the estimated prevalence of sarcopenia in the RA population ranges between 20% and 40%.[11,12] This variability may be partly attributable to differences in the diagnostic criteria used across studies.

Specifically, these criteria differ in the emphasis placed on low muscle mass, low muscle strength, and physical performance, as well as in the indices and cutoff values used for diagnosis.[12] The increased susceptibility of patients with RA to sarcopenia, compared with the general population, is linked to inactivity associated with the disease, metabolic disruptions, and long-term corticosteroid use.[13,14] Consequently, the presence of sarcopenia in the RA population is clearly linked to greater functional impairment and a higher burden of comorbidities.[15]

Sarcopenia is a well-established predictor of all-cause mortality across various populations, including the elderly and individuals with chronic conditions like cancer and cardiovascular disease.[16-18] In the context of RA, it is a frequent comorbidity known to exacerbate functional impairment and increase the likelihood of adverse events such as fractures and falls.[19-21] This vulnerability is often compounded by the common use of corticosteroids in RA management, which can accelerate muscle degradation.[20] However, despite the well-documented association between sarcopenia and these adverse physical outcomes in RA, its specific contribution to the mortality burden in this population remains poorly understood.

Therefore, the present study was designed to address this critical gap by investigating the association between sarcopenia and all-cause mortality in a large cohort of individuals with RA. By clarifying the prognostic significance of sarcopenia, these findings may help enhance risk stratification and inform the development of future clinical management strategies for this vulnerable patient population.

Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction

Study methods

What methods does the paper describe?

2.1. Study populations

This study obtained data from the National Health and Nutrition Examination Survey (NHANES), a nationwide program monitoring health and nutritional status through structured questionnaires, physical examinations, and laboratory tests.[22] All protocols were approved by the National Center for Health Statistics Ethics Review Board, and written informed consent was obtained from all participants. Data from ten consecutive cycles (1999 to 2018) were analyzed. Of the initial 101,316 participants, 34,763 individuals under 20 years old were excluded. Moreover, 20,737 individuals without RA status and 44,890 individuals with missing sarcopenia data were excluded.

Finally, 16 individuals without complete mortality data were removed, resulting in a final cohort of 910 participants (Fig. 1).

Figure 1.

Flow chart. NHANES = National Health and Nutrition Examination Survey.

Figure image at the original source: open the original paper. This file is not included in this text import.

2.2. RA population

Rheumatoid arthritis was determined through self-reported responses based on an interview, with similar efficiency compared to clinical assessments confirmed by previous investigations.[23,24] Participants were first asked whether they had ever been diagnosed with any form of arthritis by a healthcare professional. Those who answered affirmatively were then prompted to specify the type, with some individuals being diagnosed with rheumatoid arthritis.

2.3. Definition of sarcopenia

Sarcopenia was identified using appendicular skeletal muscle mass (ASM)/body mass index (BMI). ASM was calculated by adding lean soft tissue from both upper and lower limbs, which was quantified through dual-energy x-ray absorptiometry (DXA). In NHANES, whole-body DXA scans were performed using Hologic QDR 4500A fan-beam densitometers in 1999 to 2006 and Hologic Discovery A densitometers in 2011 to 2018 according to standardized procedures. Examinations were conducted by certified radiology technologists with routine quality-control measures, including phantom scans and centralized review.

To account for inter-individual variation in body composition, ASM was standardized by dividing BMI, producing a relative muscle index. Following diagnostic thresholds established by the FNIH, individuals with an ASM/BMI ratio below 0.789 for men or 0.512 for women were classified as having sarcopenia.[25,26] Determination of sarcopenia status focused on participants with an affirmative RA diagnosis and available DXA records. Ineligibility for DXA examination was associated with pregnancy or body dimensions exceeding the scanner limits of 192.5 cm in height or 136.4 kg in weight.[27]

2.4. Outcome ascertainment

Mortality status was determined from records of the National Death Index, a comprehensive vital status database maintained by the National Center for Health Statistics (NCHS). The follow-up period was calculated from the date of enrollment to the date of death or December 31, 2019, whichever occurred first. Participants who did not meet NCHS criteria for determining mortality status were excluded from the analysis.[28] This study focused exclusively on all-cause mortality, without further classification by specific causes of death.

2.5. Assessment of covariates

Covariates included age, sex, ethnicity, education level, marital status, poverty-to-income ratio (PIR), smoking status, alcohol intake, physical activity, BMI, hypertension, hyperlipidemia, diabetes mellitus, cardiovascular disease, HbA1c, total cholesterol, and uric acid, all defined following NHANES protocols.[29] Demographic and lifestyle factors were collected via structured interviews. Physical activity was assessed using the NHANES physical activity questionnaire and quantified as metabolic equivalent of task (MET)-min/wk based on activity type, weekly frequency, and duration. Comorbidities were identified through a combination of self-reported diagnoses, medication use, clinical evaluation, and laboratory tests.

Hypertension was diagnosed by a history of diagnosis, antihypertensive medication use, or blood pressure ≥ 140/90 mm Hg. Hyperlipidemia was based on diagnosis, lipid-lowering treatment, or abnormal cholesterol levels. Diabetes mellitus was determined by reported history, antidiabetic medication use, fasting glucose ≥ 126 mg/dL, or HbA1c ≥ 6.5%. Laboratory indicators were obtained using standardized NHANES assay procedures.

2.6. Statistical analysis

Baseline characteristics were compared between participants with and without sarcopenia. Continuous variables were presented as means with standard deviations or medians with interquartile ranges and were compared using the t test or Wilcoxon test, as appropriate. Categorical variables were presented as counts and percentages and compared using chi-square or Fisher test. Three cox regression models were utilized, with results shown in hazard ratio (HR) and 95% confidence interval (CI). The proportional hazards assumption was evaluated using Schoenfeld residuals, and no violation was detected (Fig. S1, Supplemental Digital Content 1).

Model 1 was unadjusted; model 2 was adjusted for demographic factors; model 3 included additional adjustments for BMI, smoking status, alcohol intake, hypertension, hyperlipidemia, diabetes mellitus, cardiovascular disease, total cholesterol, HbA1c and serum uric acid. Survival analysis with the log-rank test was carried out to compare all-cause mortality between sarcopenic and non-sarcopenic participants. Subgroup analyses were conducted to assess the consistency of the association between sarcopenia and mortality across demographic and clinical strata based on model 3. Additionally, interaction terms were tested to assess effect modification.

Missing values in categorical covariates were handled by coding missingness as an additional category, allowing all participants to be included in the primary analysis. Sensitivity analyses were performed to verify the robustness of the main findings, including a complete-case analysis and additional analyses in which model 3 was further adjusted for serum 25-hydroxyvitamin D or physical activity (MET-min/wk). All statistical analyses were performed using R software (version 4.4.1; R Foundation for Statistical Computing, Vienna, Austria). Sampling weights were not applied since we focused on internal associations within a defined analytic cohort rather than producing nationally representative estimates.

A P-value < .05 was considered statistically significant (2-tailed).

Source: 2. Materials and methods Source: 2. Materials and methods Source: 2. Materials and methods Source: 2. Materials and methods Source: 2. Materials and methods Source: 2. Materials and methods

Results: Baseline characteristics

Baseline characteristics of the 910 RA participants stratified by sarcopenia status are shown in Table 1. A total of 180 individuals (19.78%) were identified as having sarcopenia. According to our findings, participants with sarcopenia were significantly older (63.15 vs 55.51 years) and had a lower educational level. Moreover, a higher incidence of diabetes mellitus (40.00% vs 18.36%), cardiovascular disease (33.33% vs 19.86%), hypertension (66.67% vs 56.44%), and hyperlipidemia (86.11% vs 76.03%) was observed. Mexican Americans had the highest prevalence of sarcopenia (44.07%), followed by Other Hispanics (20.37%), Non-Hispanic Whites (18.27%), Other Races (14.29%), and Non-Hispanic Blacks (4.74%).

Sarcopenic participants also had higher HbA1c levels (6.12 vs 5.78) and serum uric acid concentrations (5.71 vs 5.43 mg/dL), along with a greater prevalence of obesity (BMI > 30 kg/m2: 57.22% vs 37.40%). Additionally, they were identified with lower income levels indicated by PIR and had significant differences in alcohol intake. No significant differences were observed regarding sex, smoking status, total cholesterol, and 25-hydroxyvitamin D (all P > .05).

Table 1

Baseline characteristics of participants stratified by sarcopenia status.

CharacteristicsTotal (n = 910)SarcopeniaP value
No (n = 730)Yes (n = 180)
Age, mean (SD)57.02 (14.37)55.51 (14.26)63.15 (13.19)<.001
Sex, n (%).682
 Male372 (40.88)296 (40.55)76 (42.22)
 Female538 (59.12)434 (59.45)104 (57.78)
Ethnicity, n (%)<.001
 Mexican American177 (19.45)99 (13.56)78 (43.33)
 Other Hispanic54 (5.93)43 (5.89)11 (6.11)
 Non-Hispanic White405 (44.51)331 (45.34)74 (41.11)
 Non-Hispanic Black232 (25.49)221 (30.27)11 (6.11)
 Other race42 (4.62)36 (4.93)6 (3.33)
Education level, n (%)<.001
 Less than high school367 (40.33)271 (37.12)96 (53.33)
 High school or equivalent229 (25.16)182 (24.93)47 (26.11)
 College or above314 (34.51)277 (37.95)37 (20.56)
Marital status, n (%).005
 Married and a partner508 (55.82)399 (54.66)109 (60.56)
 Never married70 (7.69)64 (8.77)6 (3.33)
 Widowed, divorced or separated316 (34.73)258 (35.34)58 (32.22)
 Not recorded16 (1.76)9 (1.23)7 (3.89)
Poverty to income ratio, n (%).011
 <1.3311 (34.18)240 (32.88)71 (39.44)
 1.3 to 3.5316 (34.73)251 (34.38)65 (36.11)
 >3.5213 (23.41)187 (25.62)26 (14.44)
 Not recorded70 (7.69)52 (7.12)18 (10.00)
Smoking status, n (%).138
 Never391 (42.97)307 (42.05)84 (46.67)
 Current262 (28.79)221 (30.27)41 (22.78)
 Former257 (28.24)202 (27.67)55 (30.56)
Alcohol intake, n (%).010
 Never393 (43.19)308 (42.19)85 (47.22)
 Current250 (27.47)217 (29.73)33 (18.33)
 Former223 (24.51)168 (23.01)55 (30.56)
 Not recorded44 (4.84)37 (5.07)7 (3.89)
Body mass index, n (%)<.001
 <25225 (24.73)208 (28.49)17 (9.44)
 25 to 30309 (33.96)249 (34.11)60 (33.33)
 >30376 (41.32)273 (37.40)103 (57.22)
Hypertension, n (%).013
 No378 (41.54)318 (43.56)60 (33.33)
 Yes532 (58.46)412 (56.44)120 (66.67)
Hyperlipidemia, n (%).003
 No200 (21.98)175 (23.97)25 (13.89)
 Yes710 (78.02)555 (76.03)155 (86.11)
Diabetes mellitus, n (%)<.001
 No704 (77.36)596 (81.64)108 (60.00)
 Yes206 (22.64)134 (18.36)72 (40.00)
Cardiovascular disease, n (%)<.001
 No705 (77.47)585 (80.14)120 (66.67)
 Yes205 (22.53)145 (19.86)60 (33.33)
HbA1c, %, mean (SD)5.85 (1.13)5.78 (1.11)6.12 (1.18)<.001
Total cholesterol, mmol/L, mean (SD)5.22 (1.10)5.21 (1.10)5.24 (1.12).764
Uric acid, mg/dL, mean (SD)5.49 (1.59)5.43 (1.60)5.71 (1.50).033
25-hydroxyvitamin D, (nmol/L), mean (SD)58.85 (22.98)59.27 (23.45)56.99 (20.81).321
Physical activity, MET-min/wk, median (IQR)756.00 (252.00 to 2412.07)756.00 (252.00 to 2418.10)720.00 (252.00 to 2400.00).597

HbA1c = hemoglobin A1c, IQR = interquartile range, MET = metabolic equivalent of task, SD = standard deviation.

Source: 3.1. Baseline characteristics Source: 3.1. Baseline characteristics

Associations of sarcopenia with mortality in RA patients

Results: Associations of sarcopenia with mortality in RA patients

The correlation of sarcopenia and all-cause mortality in RA patients is presented in Table 2. In unadjusted model 1, sarcopenia was significantly associated with higher mortality risk (HR = 1.864, 95% CI: 1.459 to 2.381, P < .001), which remained in model 2 (HR = 1.604, 95% CI: 1.193 to 2.158, P = .002). In model 3, the association persisted with an HR of 1.610 (95% CI: 1.192 to 2.176, P = .002), indicating the independent correlation of sarcopenia with increased mortality risk. The Kaplan: Meier curves for all-cause mortality can be found in Figure 2, showing a significantly lower survival probability in patients with sarcopenia (log-rank P < .001).

Table 2

Association of sarcopenia with all-cause mortality in RA patients.

GroupModel 1P valueModel 2P valueModel 3P value
HR (95% CI)HR (95% CI)HR (95% CI)
Non-sarcopeniaReferenceReferenceReference
Sarcopenia1.864 (1.459 to 2.381)<.0011.604 (1.193 to 2.158).0021.610 (1.192 to 2.176).002

Model 1: Unadjusted crude model.

Model 2: Adjusted model for age, sex, race/ethnicity, education level, marital status, PIR.

Model 3: Adjusted model incorporating additional adjustments for BMI, smoking, alcohol intake, hypertension, hyperlipidemia, diabetes mellitus, cardiovascular disease, total cholesterol, HbA1c, uric acid.

BMI = body mass index, CI = confidence intervals, HbA1c = hemoglobin A1c, HR = hazard ratio, PIR = poverty-to-income ratio, RA = rheumatoid arthritis.

Figure 2.

Kaplan: Meier analysis of all-cause mortality stratified by sarcopenia in RA. RA = rheumatoid arthritis.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: 3.2. Associations of sarcopenia with mortality in RA patients Source: 3.2. Associations of sarcopenia with mortality in RA patients Source: 3.2. Associations of sarcopenia with mortality in RA patients

Results: Subgroup analyses

The correlation was validated in several subgroups, as presented in Table 3. Sarcopenia was significantly associated with a higher mortality risk in patients aged <60 years (HR = 2.312, 95% CI: 1.081 to 4.946, P = .031), but not in the population ≥60 years old (HR = 1.257, 95% CI: 0.897 to 1.761, P = .183). A significantly higher mortality risk was observed in males with sarcopenia (HR = 2.305, 95% CI: 1.463 to 3.632, P < .001), but not in females (HR = 1.283, 95% CI: 0.820 to 2.009, P = .276).

Regarding lifestyle and clinical factors, sarcopenia contributed to higher mortality risk in current smokers (HR = 2.596, 95% CI: 1.310 to 5.145, P = .006) and current drinkers (HR = 2.021, 95% CI: 1.282 to 3.184, P = .002), as well as in patients with a BMI between 25 and 30 (HR = 3.307, 95% CI: 1.956 to 5.592, P < .001), hypertension (HR = 2.580, 95% CI: 1.372 to 4.853, P = .003), diabetes mellitus (HR = 2.126, 95% CI: 1.240 to 3.645, P = .006), cardiovascular disease (HR = 1.738, 95% CI: 1.161 to 2.602, P = .007), and hyperlipidemia (HR = 1.449, 95% CI: 1.012 to 2.073, P = .043).

No significant interaction was detected between sarcopenia and any of the stratifying variables (all P for interaction > .05). All subgroup analyses were performed using model 3, adjusting for relevant covariates while excluding the stratification variable in each specific subgroup.

Table 3

Association of sarcopenia with all-cause mortality across subgroups of RA patients.

SubgroupsNHR (95% CI)P valueP interaction
Age.730
 <605002.312 (1.081 to 4.946).031
 ≥604101.257 (0.897 to 1.761).183
Sex.074
 Male3722.305 (1.463 to 3.632)<.001
 Female5381.283 (0.820 to 2.009).276
Ethnicity.517
 Mexican American1771.219 (0.596 to 2.494).587
 Other Hispanic541.274 (0.921 to 1.762).143
 Non-Hispanic White4051.496 (0.987 to 2.268).058
 Non-Hispanic Black2321.806 (0.577 to 5.648).310
 Other race421.155 (0.846 to 1.576).364
Education level.802
 Less than high school3671.295 (0.811 to 2.068).278
 High school or equivalent2291.283 (0.731 to 2.252).385
 College or above3141.852 (0.785 to 4.372).160
Smoking status.338
 Never3911.381 (0.837 to 2.279).206
 Current2622.596 (1.310 to 5.145).006
 Former2571.729 (0.991 to 3.015).054
Alcohol intake.480
 Never3931.050 (0.426 to 2.587).915
 Current2502.021 (1.282 to 3.184).002
 Former2231.324 (0.758 to 2.313).325
Body mass index.125
 <252251.006 (0.409 to 2.475).990
 25 to 303093.307 (1.956 to 5.592)<.001
 >303761.380 (0.830 to 2.295).214
Hypertension.094
 No3781.271 (0.876 to 1.843).206
 Yes5322.580 (1.372 to 4.853).003
Hyperlipidemia.659
 No2001.447 (0.916 to 2.285).113
 Yes7101.449 (1.012 to 2.073).043
Diabetes mellitus.155
 No7041.369 (0.919 to 2.039).122
 Yes2062.126 (1.240 to 3.645).006
Cardiovascular disease.911
 No7051.543 (0.912 to 2.612).106
 Yes2051.738 (1.161 to 2.602).007

In subgroup analyses, model 3 was applied while excluding the stratification variable from covariate adjustments within each specific subgroup.

CI = confidence intervals, HR = hazard ratio, RA = rheumatoid arthritis.

Source: 3.3. Subgroup analyses Source: 3.3. Subgroup analyses

Results: Sensitivity analyses

In the sensitivity analysis, baseline characteristics of 758 participants with complete covariate data (Table S1, Supplemental Digital Content 2) were included. Sarcopenia played a significant role in increasing all-cause mortality across all models, consistent with the primary analysis. In the unadjusted model (model 1), the HR for sarcopenia was 1.846 (95% CI: 1.402 to 2.430, P < .001), which adjusted to 1.658 (95% CI: 1.221 to 2.250, P = .001) in model 2, and 1.593 (95% CI: 1.146 to 2.215, P = .006) in model 3 (Table S2, Supplemental Digital Content 3).

The association remained significant after additional adjustment for serum 25-hydroxyvitamin D (HR = 1.652, 95% CI: 1.102 to 2.477, P = .015) and physical activity (HR = 1.632, 95% CI: 1.082 to 2.462, P = .019). Survival analysis with Kaplan: Meier curves (Fig. S2, Supplemental Digital Content 4) further confirmed the findings, showing a significantly lower survival probability in sarcopenic patients (log-rank P < .001), confirming the correlation observed in the primary analysis.

Source: 3.4. Sensitivity analyses

Discussion

This study showed an association between sarcopenia and increased all-cause mortality in patients with RA. After adjusting for multiple confounders, sarcopenia was associated with a 61% higher risk of mortality, and this association remained consistent in sensitivity analyses. This finding suggests that muscle health warrants attention in this population and that early management of sarcopenia may be beneficial to long-term survival.

Our finding that sarcopenia is significantly associated with all-cause mortality in patients with RA is consistent with a large body of evidence from diverse populations. For instance, a meta-analysis by Xu et al[30] demonstrated a significant mortality association (HR = 2.00), while another by Westbury et al[8] reported a pooled HR of 2.75, underscoring the consistent relationship between muscle loss and poor outcomes. This link has been further substantiated in various specific conditions, with studies in chronic kidney disease,[31] liver cirrhosis,[32] and type 2 diabetes,[33] all identifying sarcopenia as a critical factor associated with higher mortality.

Within the specific context of RA, our results are particularly aligned with key recent studies. Consistent with findings from Xu et al[34] in a smaller RA cohort of 558 patients (adjusted HR = 1.826 to 2.112), our study in a larger cohort (n = 910) confirmed a significant association with a comparable hazard ratio (adjusted HR = 1.610). Our observed sarcopenia prevalence (19.8%) was also comparable to that reported by Shin et al[35] (20.5%). Our work also builds upon that of Bennett et al,[9] who previously highlighted the link between sarcopenia and physical disability in RA.

This is further supported by Wiegmann et al,[36] who found sarcopenia in RA diminishes quality of life, and is often exacerbated by glucocorticoid use, a key factor identified by Yamada et al.[37] Moreover, its synergistic effects with osteoporosis are known to significantly increase fracture likelihood.[20,38,39] While these previous studies established a clear link between sarcopenia and adverse physical outcomes, our longitudinal analysis extends this by demonstrating its significant association with all-cause mortality. Additionally, our subgroup analysis revealed that the strength of this association varies by patient characteristics.

Collectively, these findings suggest the potential value of integrating sarcopenia assessment into the clinical management of RA, a strategy that may aid in refining patient stratification and better informing long-term prognosis.

The association between sarcopenia and all-cause mortality in patients with RA appears to be context-dependent, varying by demographic factors such as sex and age. The heightened vulnerability observed in males, a group in whom RA is linked to more pronounced lean mass deficits,[40] may be explained by the pivotal role of testosterone. Low testosterone levels present a dual challenge for these patients: they are not only associated with an increased risk of developing RA itself,[41] but are also fundamental to maintaining muscle mass,[42] partly by mitigating muscle wasting[43] and reducing protein breakdown.[44] In addition to these sex-specific factors, the observation that this association was more pronounced in younger than in older adults is also insightful.

This may suggest that in younger individuals, sarcopenia serves as a more direct indicator of a severe underlying disease phenotype, whereas in older adults, its prognostic signal is likely attenuated by the confounding influence of natural, age-related muscle decline.[45Not reported47]

The development of sarcopenia in RA is multifactorial, driven by both the inherent inflammatory state of the disease and common therapeutic interventions. Chronic inflammation in RA is a primary driver of muscle degradation. Key inflammatory cytokines, particularly tumor necrosis factor-alpha and interleukin-6, are known to activate proteolytic pathways that lead to muscle wasting.[48] This inflammatory environment may also alter macrophage polarization towards a pro-catabolic M1 phenotype,[49,50] while concurrent metabolic disruptions, including altered lipid metabolism and impaired protein synthesis, further contribute to the loss of muscle mass.[51,52] Compounding these disease-driven processes, glucocorticoid (GC) therapy, a common component of RA management, significantly exacerbates muscle atrophy.

GCs are known to directly interfere with muscle health by reducing both mass and function,[53] with higher doses linked to a greater likelihood of muscle loss.[37] Mechanistically, GCs promote muscle degradation by upregulating key catabolic regulators like myostatin and atrogenes, such as atrogin-1 and MuRF-1.[54] The deleterious impact of these therapies is often amplified by vitamin D deficiency, a common issue in patients undergoing GC treatment.[55] These findings, therefore, suggest that sarcopenia may reflect an underlying systemic burden that is also associated with all-cause mortality in patients with RA.

This study has several strengths. First, we used the NHANES database, which provided a large sample size and established a solid foundation for our analysis. Second, our Cox regression models controlled for a wide range of demographic, clinical, and lifestyle indicators, which supports the robustness of the results. Additionally, subgroup and sensitivity analyses were conducted to further validate our findings. However, this study also has several limitations. To begin with, the reliance on self-reported data, such as the RA diagnosis, is a potential source of information bias, even if the method has been previously validated.

The assessment of sarcopenia using body composition data could also be influenced by potential measurement errors. Furthermore, our analysis did not account for several important clinical variables, such as disease activity, specific treatment regimens, or nutritional status, and the absence of these data introduces the possibility of residual confounding. Lastly, the retrospective nature of the data limited our ability to control for dynamic changes in disease progression over time. Therefore, the long-term relationship between sarcopenia and mortality in patients with RA needs to be further investigated with prospective studies.

Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion

Results

3.1. Baseline characteristics

Baseline characteristics of the 910 RA participants stratified by sarcopenia status are shown in Table 1. A total of 180 individuals (19.78%) were identified as having sarcopenia. According to our findings, participants with sarcopenia were significantly older (63.15 vs 55.51 years) and had a lower educational level. Moreover, a higher incidence of diabetes mellitus (40.00% vs 18.36%), cardiovascular disease (33.33% vs 19.86%), hypertension (66.67% vs 56.44%), and hyperlipidemia (86.11% vs 76.03%) was observed. Mexican Americans had the highest prevalence of sarcopenia (44.07%), followed by Other Hispanics (20.37%), Non-Hispanic Whites (18.27%), Other Races (14.29%), and Non-Hispanic Blacks (4.74%).

Sarcopenic participants also had higher HbA1c levels (6.12 vs 5.78) and serum uric acid concentrations (5.71 vs 5.43 mg/dL), along with a greater prevalence of obesity (BMI > 30 kg/m2: 57.22% vs 37.40%). Additionally, they were identified with lower income levels indicated by PIR and had significant differences in alcohol intake. No significant differences were observed regarding sex, smoking status, total cholesterol, and 25-hydroxyvitamin D (all P > .05).

Table 1

Baseline characteristics of participants stratified by sarcopenia status.

CharacteristicsTotal (n = 910)SarcopeniaP value
No (n = 730)Yes (n = 180)
Age, mean (SD)57.02 (14.37)55.51 (14.26)63.15 (13.19)<.001
Sex, n (%).682
 Male372 (40.88)296 (40.55)76 (42.22)
 Female538 (59.12)434 (59.45)104 (57.78)
Ethnicity, n (%)<.001
 Mexican American177 (19.45)99 (13.56)78 (43.33)
 Other Hispanic54 (5.93)43 (5.89)11 (6.11)
 Non-Hispanic White405 (44.51)331 (45.34)74 (41.11)
 Non-Hispanic Black232 (25.49)221 (30.27)11 (6.11)
 Other race42 (4.62)36 (4.93)6 (3.33)
Education level, n (%)<.001
 Less than high school367 (40.33)271 (37.12)96 (53.33)
 High school or equivalent229 (25.16)182 (24.93)47 (26.11)
 College or above314 (34.51)277 (37.95)37 (20.56)
Marital status, n (%).005
 Married and a partner508 (55.82)399 (54.66)109 (60.56)
 Never married70 (7.69)64 (8.77)6 (3.33)
 Widowed, divorced or separated316 (34.73)258 (35.34)58 (32.22)
 Not recorded16 (1.76)9 (1.23)7 (3.89)
Poverty to income ratio, n (%).011
 <1.3311 (34.18)240 (32.88)71 (39.44)
 1.3 to 3.5316 (34.73)251 (34.38)65 (36.11)
 >3.5213 (23.41)187 (25.62)26 (14.44)
 Not recorded70 (7.69)52 (7.12)18 (10.00)
Smoking status, n (%).138
 Never391 (42.97)307 (42.05)84 (46.67)
 Current262 (28.79)221 (30.27)41 (22.78)
 Former257 (28.24)202 (27.67)55 (30.56)
Alcohol intake, n (%).010
 Never393 (43.19)308 (42.19)85 (47.22)
 Current250 (27.47)217 (29.73)33 (18.33)
 Former223 (24.51)168 (23.01)55 (30.56)
 Not recorded44 (4.84)37 (5.07)7 (3.89)
Body mass index, n (%)<.001
 <25225 (24.73)208 (28.49)17 (9.44)
 25 to 30309 (33.96)249 (34.11)60 (33.33)
 >30376 (41.32)273 (37.40)103 (57.22)
Hypertension, n (%).013
 No378 (41.54)318 (43.56)60 (33.33)
 Yes532 (58.46)412 (56.44)120 (66.67)
Hyperlipidemia, n (%).003
 No200 (21.98)175 (23.97)25 (13.89)
 Yes710 (78.02)555 (76.03)155 (86.11)
Diabetes mellitus, n (%)<.001
 No704 (77.36)596 (81.64)108 (60.00)
 Yes206 (22.64)134 (18.36)72 (40.00)
Cardiovascular disease, n (%)<.001
 No705 (77.47)585 (80.14)120 (66.67)
 Yes205 (22.53)145 (19.86)60 (33.33)
HbA1c, %, mean (SD)5.85 (1.13)5.78 (1.11)6.12 (1.18)<.001
Total cholesterol, mmol/L, mean (SD)5.22 (1.10)5.21 (1.10)5.24 (1.12).764
Uric acid, mg/dL, mean (SD)5.49 (1.59)5.43 (1.60)5.71 (1.50).033
25-hydroxyvitamin D, (nmol/L), mean (SD)58.85 (22.98)59.27 (23.45)56.99 (20.81).321
Physical activity, MET-min/wk, median (IQR)756.00 (252.00 to 2412.07)756.00 (252.00 to 2418.10)720.00 (252.00 to 2400.00).597

HbA1c = hemoglobin A1c, IQR = interquartile range, MET = metabolic equivalent of task, SD = standard deviation.

3.2. Associations of sarcopenia with mortality in RA patients

The correlation of sarcopenia and all-cause mortality in RA patients is presented in Table 2. In unadjusted model 1, sarcopenia was significantly associated with higher mortality risk (HR = 1.864, 95% CI: 1.459 to 2.381, P < .001), which remained in model 2 (HR = 1.604, 95% CI: 1.193 to 2.158, P = .002). In model 3, the association persisted with an HR of 1.610 (95% CI: 1.192 to 2.176, P = .002), indicating the independent correlation of sarcopenia with increased mortality risk. The Kaplan: Meier curves for all-cause mortality can be found in Figure 2, showing a significantly lower survival probability in patients with sarcopenia (log-rank P < .001).

Table 2

Association of sarcopenia with all-cause mortality in RA patients.

GroupModel 1P valueModel 2P valueModel 3P value
HR (95% CI)HR (95% CI)HR (95% CI)
Non-sarcopeniaReferenceReferenceReference
Sarcopenia1.864 (1.459 to 2.381)<.0011.604 (1.193 to 2.158).0021.610 (1.192 to 2.176).002

Model 1: Unadjusted crude model.

Model 2: Adjusted model for age, sex, race/ethnicity, education level, marital status, PIR.

Model 3: Adjusted model incorporating additional adjustments for BMI, smoking, alcohol intake, hypertension, hyperlipidemia, diabetes mellitus, cardiovascular disease, total cholesterol, HbA1c, uric acid.

BMI = body mass index, CI = confidence intervals, HbA1c = hemoglobin A1c, HR = hazard ratio, PIR = poverty-to-income ratio, RA = rheumatoid arthritis.

Figure 2.

Kaplan: Meier analysis of all-cause mortality stratified by sarcopenia in RA. RA = rheumatoid arthritis.

Figure image at the original source: open the original paper. This file is not included in this text import.

3.3. Subgroup analyses

The correlation was validated in several subgroups, as presented in Table 3. Sarcopenia was significantly associated with a higher mortality risk in patients aged <60 years (HR = 2.312, 95% CI: 1.081 to 4.946, P = .031), but not in the population ≥60 years old (HR = 1.257, 95% CI: 0.897 to 1.761, P = .183). A significantly higher mortality risk was observed in males with sarcopenia (HR = 2.305, 95% CI: 1.463 to 3.632, P < .001), but not in females (HR = 1.283, 95% CI: 0.820 to 2.009, P = .276).

Regarding lifestyle and clinical factors, sarcopenia contributed to higher mortality risk in current smokers (HR = 2.596, 95% CI: 1.310 to 5.145, P = .006) and current drinkers (HR = 2.021, 95% CI: 1.282 to 3.184, P = .002), as well as in patients with a BMI between 25 and 30 (HR = 3.307, 95% CI: 1.956 to 5.592, P < .001), hypertension (HR = 2.580, 95% CI: 1.372 to 4.853, P = .003), diabetes mellitus (HR = 2.126, 95% CI: 1.240 to 3.645, P = .006), cardiovascular disease (HR = 1.738, 95% CI: 1.161 to 2.602, P = .007), and hyperlipidemia (HR = 1.449, 95% CI: 1.012 to 2.073, P = .043).

No significant interaction was detected between sarcopenia and any of the stratifying variables (all P for interaction > .05). All subgroup analyses were performed using model 3, adjusting for relevant covariates while excluding the stratification variable in each specific subgroup.

Table 3

Association of sarcopenia with all-cause mortality across subgroups of RA patients.

SubgroupsNHR (95% CI)P valueP interaction
Age.730
 <605002.312 (1.081 to 4.946).031
 ≥604101.257 (0.897 to 1.761).183
Sex.074
 Male3722.305 (1.463 to 3.632)<.001
 Female5381.283 (0.820 to 2.009).276
Ethnicity.517
 Mexican American1771.219 (0.596 to 2.494).587
 Other Hispanic541.274 (0.921 to 1.762).143
 Non-Hispanic White4051.496 (0.987 to 2.268).058
 Non-Hispanic Black2321.806 (0.577 to 5.648).310
 Other race421.155 (0.846 to 1.576).364
Education level.802
 Less than high school3671.295 (0.811 to 2.068).278
 High school or equivalent2291.283 (0.731 to 2.252).385
 College or above3141.852 (0.785 to 4.372).160
Smoking status.338
 Never3911.381 (0.837 to 2.279).206
 Current2622.596 (1.310 to 5.145).006
 Former2571.729 (0.991 to 3.015).054
Alcohol intake.480
 Never3931.050 (0.426 to 2.587).915
 Current2502.021 (1.282 to 3.184).002
 Former2231.324 (0.758 to 2.313).325
Body mass index.125
 <252251.006 (0.409 to 2.475).990
 25 to 303093.307 (1.956 to 5.592)<.001
 >303761.380 (0.830 to 2.295).214
Hypertension.094
 No3781.271 (0.876 to 1.843).206
 Yes5322.580 (1.372 to 4.853).003
Hyperlipidemia.659
 No2001.447 (0.916 to 2.285).113
 Yes7101.449 (1.012 to 2.073).043
Diabetes mellitus.155
 No7041.369 (0.919 to 2.039).122
 Yes2062.126 (1.240 to 3.645).006
Cardiovascular disease.911
 No7051.543 (0.912 to 2.612).106
 Yes2051.738 (1.161 to 2.602).007

In subgroup analyses, model 3 was applied while excluding the stratification variable from covariate adjustments within each specific subgroup.

CI = confidence intervals, HR = hazard ratio, RA = rheumatoid arthritis.

3.4. Sensitivity analyses

In the sensitivity analysis, baseline characteristics of 758 participants with complete covariate data (Table S1, Supplemental Digital Content 2) were included. Sarcopenia played a significant role in increasing all-cause mortality across all models, consistent with the primary analysis. In the unadjusted model (model 1), the HR for sarcopenia was 1.846 (95% CI: 1.402 to 2.430, P < .001), which adjusted to 1.658 (95% CI: 1.221 to 2.250, P = .001) in model 2, and 1.593 (95% CI: 1.146 to 2.215, P = .006) in model 3 (Table S2, Supplemental Digital Content 3).

The association remained significant after additional adjustment for serum 25-hydroxyvitamin D (HR = 1.652, 95% CI: 1.102 to 2.477, P = .015) and physical activity (HR = 1.632, 95% CI: 1.082 to 2.462, P = .019). Survival analysis with Kaplan: Meier curves (Fig. S2, Supplemental Digital Content 4) further confirmed the findings, showing a significantly lower survival probability in sarcopenic patients (log-rank P < .001), confirming the correlation observed in the primary analysis.

Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results

Conclusion

The present longitudinal analysis identifies an association between sarcopenia and an elevated risk of all-cause mortality among patients with RA. This finding underscores the clinical relevance of monitoring skeletal muscle health in this population. Furthermore, the observed association provides a rationale for future research to evaluate the relationship between muscle status and long-term outcomes.

Source: 5. Conclusion
Authors’ abstract

Sarcopenia, characterized by a decline in muscle mass and function, is increasingly recognized as a significant comorbidity in chronic diseases, including rheumatoid arthritis (RA). However, its relevance to all-cause mortality in RA patients remains to be explored. Here, we examine the correlation between sarcopenia and all-cause mortality in RA patients using the NHANES database. Data were obtained from 910 RA patients identified through self-reported data in the nationwide NHANES (1999 to 2018). Sarcopenia was defined by an appendicular skeletal muscle mass index adjusted for body mass index (ASM/BMI).

Cox regression models were utilized to measure the connection between sarcopenia and all-cause mortality, adjusted for demographic, clinical, and lifestyle factors. Moreover, subgroup and sensitivity analyses were also performed. Sarcopenia was independently linked to a higher risk of all-cause mortality (HR = 1.610, 95% CI: 1.192 to 2.176, P = .002) after adjusting for potential confounders. Subgroup analysis showed significant associations in individuals aged <60 years, males, and those with comorbid conditions such as hypertension, diabetes, and cardiovascular disease. Additionally, sensitivity analysis confirmed the robustness of the findings.

Sarcopenia was associated with a higher mortality risk in patients with RA, suggesting that its early identification and management may improve survival outcomes.

Read the full paper

1. Introduction

Rheumatoid arthritis (RA) is a systemic autoimmune disorder characterized by chronic inflammation that leads to progressive organ damage. Despite significant therapeutic advances over the past decades, including the widespread use of disease-modifying antirheumatic drugs and targeted therapies, patients with RA continue to face a significantly higher all-cause mortality than the general population.[1-3] This enduring mortality gap is quantified by standardized mortality ratios reported between 1.4 and 2.1 in large-scale cohort studies.[4-6]

Sarcopenia is defined by the Foundation for the National Institutes of Health (FNIH) Sarcopenia Project as the combination of low lean mass and muscle weakness associated with disability, frailty, and all-cause mortality.[7,8] Sarcopenia affects not only the elderly but also individuals with chronic inflammatory diseases, where systemic inflammation, metabolic disruption, and reduced physical activity contribute to muscle degradation.[9,10] Previous investigations indicate that the estimated prevalence of sarcopenia in the RA population ranges between 20% and 40%.[11,12] This variability may be partly attributable to differences in the diagnostic criteria used across studies.

Specifically, these criteria differ in the emphasis placed on low muscle mass, low muscle strength, and physical performance, as well as in the indices and cutoff values used for diagnosis.[12] The increased susceptibility of patients with RA to sarcopenia, compared with the general population, is linked to inactivity associated with the disease, metabolic disruptions, and long-term corticosteroid use.[13,14] Consequently, the presence of sarcopenia in the RA population is clearly linked to greater functional impairment and a higher burden of comorbidities.[15]

Sarcopenia is a well-established predictor of all-cause mortality across various populations, including the elderly and individuals with chronic conditions like cancer and cardiovascular disease.[16-18] In the context of RA, it is a frequent comorbidity known to exacerbate functional impairment and increase the likelihood of adverse events such as fractures and falls.[19-21] This vulnerability is often compounded by the common use of corticosteroids in RA management, which can accelerate muscle degradation.[20] However, despite the well-documented association between sarcopenia and these adverse physical outcomes in RA, its specific contribution to the mortality burden in this population remains poorly understood.

Therefore, the present study was designed to address this critical gap by investigating the association between sarcopenia and all-cause mortality in a large cohort of individuals with RA. By clarifying the prognostic significance of sarcopenia, these findings may help enhance risk stratification and inform the development of future clinical management strategies for this vulnerable patient population.

2. Materials and methods

2.1. Study populations

This study obtained data from the National Health and Nutrition Examination Survey (NHANES), a nationwide program monitoring health and nutritional status through structured questionnaires, physical examinations, and laboratory tests.[22] All protocols were approved by the National Center for Health Statistics Ethics Review Board, and written informed consent was obtained from all participants. Data from ten consecutive cycles (1999 to 2018) were analyzed. Of the initial 101,316 participants, 34,763 individuals under 20 years old were excluded. Moreover, 20,737 individuals without RA status and 44,890 individuals with missing sarcopenia data were excluded.

Finally, 16 individuals without complete mortality data were removed, resulting in a final cohort of 910 participants (Fig. 1).

Figure 1.

Flow chart. NHANES = National Health and Nutrition Examination Survey.

Figure image at the original source: open the original paper. This file is not included in this text import.

2.2. RA population

Rheumatoid arthritis was determined through self-reported responses based on an interview, with similar efficiency compared to clinical assessments confirmed by previous investigations.[23,24] Participants were first asked whether they had ever been diagnosed with any form of arthritis by a healthcare professional. Those who answered affirmatively were then prompted to specify the type, with some individuals being diagnosed with rheumatoid arthritis.

2.3. Definition of sarcopenia

Sarcopenia was identified using appendicular skeletal muscle mass (ASM)/body mass index (BMI). ASM was calculated by adding lean soft tissue from both upper and lower limbs, which was quantified through dual-energy x-ray absorptiometry (DXA). In NHANES, whole-body DXA scans were performed using Hologic QDR 4500A fan-beam densitometers in 1999 to 2006 and Hologic Discovery A densitometers in 2011 to 2018 according to standardized procedures. Examinations were conducted by certified radiology technologists with routine quality-control measures, including phantom scans and centralized review.

To account for inter-individual variation in body composition, ASM was standardized by dividing BMI, producing a relative muscle index. Following diagnostic thresholds established by the FNIH, individuals with an ASM/BMI ratio below 0.789 for men or 0.512 for women were classified as having sarcopenia.[25,26] Determination of sarcopenia status focused on participants with an affirmative RA diagnosis and available DXA records. Ineligibility for DXA examination was associated with pregnancy or body dimensions exceeding the scanner limits of 192.5 cm in height or 136.4 kg in weight.[27]

2.4. Outcome ascertainment

Mortality status was determined from records of the National Death Index, a comprehensive vital status database maintained by the National Center for Health Statistics (NCHS). The follow-up period was calculated from the date of enrollment to the date of death or December 31, 2019, whichever occurred first. Participants who did not meet NCHS criteria for determining mortality status were excluded from the analysis.[28] This study focused exclusively on all-cause mortality, without further classification by specific causes of death.

2.5. Assessment of covariates

Covariates included age, sex, ethnicity, education level, marital status, poverty-to-income ratio (PIR), smoking status, alcohol intake, physical activity, BMI, hypertension, hyperlipidemia, diabetes mellitus, cardiovascular disease, HbA1c, total cholesterol, and uric acid, all defined following NHANES protocols.[29] Demographic and lifestyle factors were collected via structured interviews. Physical activity was assessed using the NHANES physical activity questionnaire and quantified as metabolic equivalent of task (MET)-min/wk based on activity type, weekly frequency, and duration. Comorbidities were identified through a combination of self-reported diagnoses, medication use, clinical evaluation, and laboratory tests.

Hypertension was diagnosed by a history of diagnosis, antihypertensive medication use, or blood pressure ≥ 140/90 mm Hg. Hyperlipidemia was based on diagnosis, lipid-lowering treatment, or abnormal cholesterol levels. Diabetes mellitus was determined by reported history, antidiabetic medication use, fasting glucose ≥ 126 mg/dL, or HbA1c ≥ 6.5%. Laboratory indicators were obtained using standardized NHANES assay procedures.

2.6. Statistical analysis

Baseline characteristics were compared between participants with and without sarcopenia. Continuous variables were presented as means with standard deviations or medians with interquartile ranges and were compared using the t test or Wilcoxon test, as appropriate. Categorical variables were presented as counts and percentages and compared using chi-square or Fisher test. Three cox regression models were utilized, with results shown in hazard ratio (HR) and 95% confidence interval (CI). The proportional hazards assumption was evaluated using Schoenfeld residuals, and no violation was detected (Fig. S1, Supplemental Digital Content 1).

Model 1 was unadjusted; model 2 was adjusted for demographic factors; model 3 included additional adjustments for BMI, smoking status, alcohol intake, hypertension, hyperlipidemia, diabetes mellitus, cardiovascular disease, total cholesterol, HbA1c and serum uric acid. Survival analysis with the log-rank test was carried out to compare all-cause mortality between sarcopenic and non-sarcopenic participants. Subgroup analyses were conducted to assess the consistency of the association between sarcopenia and mortality across demographic and clinical strata based on model 3. Additionally, interaction terms were tested to assess effect modification.

Missing values in categorical covariates were handled by coding missingness as an additional category, allowing all participants to be included in the primary analysis. Sensitivity analyses were performed to verify the robustness of the main findings, including a complete-case analysis and additional analyses in which model 3 was further adjusted for serum 25-hydroxyvitamin D or physical activity (MET-min/wk). All statistical analyses were performed using R software (version 4.4.1; R Foundation for Statistical Computing, Vienna, Austria). Sampling weights were not applied since we focused on internal associations within a defined analytic cohort rather than producing nationally representative estimates.

A P-value < .05 was considered statistically significant (2-tailed).

3. Results

3.1. Baseline characteristics

Baseline characteristics of the 910 RA participants stratified by sarcopenia status are shown in Table 1. A total of 180 individuals (19.78%) were identified as having sarcopenia. According to our findings, participants with sarcopenia were significantly older (63.15 vs 55.51 years) and had a lower educational level. Moreover, a higher incidence of diabetes mellitus (40.00% vs 18.36%), cardiovascular disease (33.33% vs 19.86%), hypertension (66.67% vs 56.44%), and hyperlipidemia (86.11% vs 76.03%) was observed. Mexican Americans had the highest prevalence of sarcopenia (44.07%), followed by Other Hispanics (20.37%), Non-Hispanic Whites (18.27%), Other Races (14.29%), and Non-Hispanic Blacks (4.74%).

Sarcopenic participants also had higher HbA1c levels (6.12 vs 5.78) and serum uric acid concentrations (5.71 vs 5.43 mg/dL), along with a greater prevalence of obesity (BMI > 30 kg/m2: 57.22% vs 37.40%). Additionally, they were identified with lower income levels indicated by PIR and had significant differences in alcohol intake. No significant differences were observed regarding sex, smoking status, total cholesterol, and 25-hydroxyvitamin D (all P > .05).

Table 1

Baseline characteristics of participants stratified by sarcopenia status.

CharacteristicsTotal (n = 910)SarcopeniaP value
No (n = 730)Yes (n = 180)
Age, mean (SD)57.02 (14.37)55.51 (14.26)63.15 (13.19)<.001
Sex, n (%).682
 Male372 (40.88)296 (40.55)76 (42.22)
 Female538 (59.12)434 (59.45)104 (57.78)
Ethnicity, n (%)<.001
 Mexican American177 (19.45)99 (13.56)78 (43.33)
 Other Hispanic54 (5.93)43 (5.89)11 (6.11)
 Non-Hispanic White405 (44.51)331 (45.34)74 (41.11)
 Non-Hispanic Black232 (25.49)221 (30.27)11 (6.11)
 Other race42 (4.62)36 (4.93)6 (3.33)
Education level, n (%)<.001
 Less than high school367 (40.33)271 (37.12)96 (53.33)
 High school or equivalent229 (25.16)182 (24.93)47 (26.11)
 College or above314 (34.51)277 (37.95)37 (20.56)
Marital status, n (%).005
 Married and a partner508 (55.82)399 (54.66)109 (60.56)
 Never married70 (7.69)64 (8.77)6 (3.33)
 Widowed, divorced or separated316 (34.73)258 (35.34)58 (32.22)
 Not recorded16 (1.76)9 (1.23)7 (3.89)
Poverty to income ratio, n (%).011
 <1.3311 (34.18)240 (32.88)71 (39.44)
 1.3 to 3.5316 (34.73)251 (34.38)65 (36.11)
 >3.5213 (23.41)187 (25.62)26 (14.44)
 Not recorded70 (7.69)52 (7.12)18 (10.00)
Smoking status, n (%).138
 Never391 (42.97)307 (42.05)84 (46.67)
 Current262 (28.79)221 (30.27)41 (22.78)
 Former257 (28.24)202 (27.67)55 (30.56)
Alcohol intake, n (%).010
 Never393 (43.19)308 (42.19)85 (47.22)
 Current250 (27.47)217 (29.73)33 (18.33)
 Former223 (24.51)168 (23.01)55 (30.56)
 Not recorded44 (4.84)37 (5.07)7 (3.89)
Body mass index, n (%)<.001
 <25225 (24.73)208 (28.49)17 (9.44)
 25 to 30309 (33.96)249 (34.11)60 (33.33)
 >30376 (41.32)273 (37.40)103 (57.22)
Hypertension, n (%).013
 No378 (41.54)318 (43.56)60 (33.33)
 Yes532 (58.46)412 (56.44)120 (66.67)
Hyperlipidemia, n (%).003
 No200 (21.98)175 (23.97)25 (13.89)
 Yes710 (78.02)555 (76.03)155 (86.11)
Diabetes mellitus, n (%)<.001
 No704 (77.36)596 (81.64)108 (60.00)
 Yes206 (22.64)134 (18.36)72 (40.00)
Cardiovascular disease, n (%)<.001
 No705 (77.47)585 (80.14)120 (66.67)
 Yes205 (22.53)145 (19.86)60 (33.33)
HbA1c, %, mean (SD)5.85 (1.13)5.78 (1.11)6.12 (1.18)<.001
Total cholesterol, mmol/L, mean (SD)5.22 (1.10)5.21 (1.10)5.24 (1.12).764
Uric acid, mg/dL, mean (SD)5.49 (1.59)5.43 (1.60)5.71 (1.50).033
25-hydroxyvitamin D, (nmol/L), mean (SD)58.85 (22.98)59.27 (23.45)56.99 (20.81).321
Physical activity, MET-min/wk, median (IQR)756.00 (252.00 to 2412.07)756.00 (252.00 to 2418.10)720.00 (252.00 to 2400.00).597

HbA1c = hemoglobin A1c, IQR = interquartile range, MET = metabolic equivalent of task, SD = standard deviation.

3.2. Associations of sarcopenia with mortality in RA patients

The correlation of sarcopenia and all-cause mortality in RA patients is presented in Table 2. In unadjusted model 1, sarcopenia was significantly associated with higher mortality risk (HR = 1.864, 95% CI: 1.459 to 2.381, P < .001), which remained in model 2 (HR = 1.604, 95% CI: 1.193 to 2.158, P = .002). In model 3, the association persisted with an HR of 1.610 (95% CI: 1.192 to 2.176, P = .002), indicating the independent correlation of sarcopenia with increased mortality risk. The Kaplan: Meier curves for all-cause mortality can be found in Figure 2, showing a significantly lower survival probability in patients with sarcopenia (log-rank P < .001).

Table 2

Association of sarcopenia with all-cause mortality in RA patients.

GroupModel 1P valueModel 2P valueModel 3P value
HR (95% CI)HR (95% CI)HR (95% CI)
Non-sarcopeniaReferenceReferenceReference
Sarcopenia1.864 (1.459 to 2.381)<.0011.604 (1.193 to 2.158).0021.610 (1.192 to 2.176).002

Model 1: Unadjusted crude model.

Model 2: Adjusted model for age, sex, race/ethnicity, education level, marital status, PIR.

Model 3: Adjusted model incorporating additional adjustments for BMI, smoking, alcohol intake, hypertension, hyperlipidemia, diabetes mellitus, cardiovascular disease, total cholesterol, HbA1c, uric acid.

BMI = body mass index, CI = confidence intervals, HbA1c = hemoglobin A1c, HR = hazard ratio, PIR = poverty-to-income ratio, RA = rheumatoid arthritis.

Figure 2.

Kaplan: Meier analysis of all-cause mortality stratified by sarcopenia in RA. RA = rheumatoid arthritis.

Figure image at the original source: open the original paper. This file is not included in this text import.

3.3. Subgroup analyses

The correlation was validated in several subgroups, as presented in Table 3. Sarcopenia was significantly associated with a higher mortality risk in patients aged <60 years (HR = 2.312, 95% CI: 1.081 to 4.946, P = .031), but not in the population ≥60 years old (HR = 1.257, 95% CI: 0.897 to 1.761, P = .183). A significantly higher mortality risk was observed in males with sarcopenia (HR = 2.305, 95% CI: 1.463 to 3.632, P < .001), but not in females (HR = 1.283, 95% CI: 0.820 to 2.009, P = .276).

Regarding lifestyle and clinical factors, sarcopenia contributed to higher mortality risk in current smokers (HR = 2.596, 95% CI: 1.310 to 5.145, P = .006) and current drinkers (HR = 2.021, 95% CI: 1.282 to 3.184, P = .002), as well as in patients with a BMI between 25 and 30 (HR = 3.307, 95% CI: 1.956 to 5.592, P < .001), hypertension (HR = 2.580, 95% CI: 1.372 to 4.853, P = .003), diabetes mellitus (HR = 2.126, 95% CI: 1.240 to 3.645, P = .006), cardiovascular disease (HR = 1.738, 95% CI: 1.161 to 2.602, P = .007), and hyperlipidemia (HR = 1.449, 95% CI: 1.012 to 2.073, P = .043).

No significant interaction was detected between sarcopenia and any of the stratifying variables (all P for interaction > .05). All subgroup analyses were performed using model 3, adjusting for relevant covariates while excluding the stratification variable in each specific subgroup.

Table 3

Association of sarcopenia with all-cause mortality across subgroups of RA patients.

SubgroupsNHR (95% CI)P valueP interaction
Age.730
 <605002.312 (1.081 to 4.946).031
 ≥604101.257 (0.897 to 1.761).183
Sex.074
 Male3722.305 (1.463 to 3.632)<.001
 Female5381.283 (0.820 to 2.009).276
Ethnicity.517
 Mexican American1771.219 (0.596 to 2.494).587
 Other Hispanic541.274 (0.921 to 1.762).143
 Non-Hispanic White4051.496 (0.987 to 2.268).058
 Non-Hispanic Black2321.806 (0.577 to 5.648).310
 Other race421.155 (0.846 to 1.576).364
Education level.802
 Less than high school3671.295 (0.811 to 2.068).278
 High school or equivalent2291.283 (0.731 to 2.252).385
 College or above3141.852 (0.785 to 4.372).160
Smoking status.338
 Never3911.381 (0.837 to 2.279).206
 Current2622.596 (1.310 to 5.145).006
 Former2571.729 (0.991 to 3.015).054
Alcohol intake.480
 Never3931.050 (0.426 to 2.587).915
 Current2502.021 (1.282 to 3.184).002
 Former2231.324 (0.758 to 2.313).325
Body mass index.125
 <252251.006 (0.409 to 2.475).990
 25 to 303093.307 (1.956 to 5.592)<.001
 >303761.380 (0.830 to 2.295).214
Hypertension.094
 No3781.271 (0.876 to 1.843).206
 Yes5322.580 (1.372 to 4.853).003
Hyperlipidemia.659
 No2001.447 (0.916 to 2.285).113
 Yes7101.449 (1.012 to 2.073).043
Diabetes mellitus.155
 No7041.369 (0.919 to 2.039).122
 Yes2062.126 (1.240 to 3.645).006
Cardiovascular disease.911
 No7051.543 (0.912 to 2.612).106
 Yes2051.738 (1.161 to 2.602).007

In subgroup analyses, model 3 was applied while excluding the stratification variable from covariate adjustments within each specific subgroup.

CI = confidence intervals, HR = hazard ratio, RA = rheumatoid arthritis.

3.4. Sensitivity analyses

In the sensitivity analysis, baseline characteristics of 758 participants with complete covariate data (Table S1, Supplemental Digital Content 2) were included. Sarcopenia played a significant role in increasing all-cause mortality across all models, consistent with the primary analysis. In the unadjusted model (model 1), the HR for sarcopenia was 1.846 (95% CI: 1.402 to 2.430, P < .001), which adjusted to 1.658 (95% CI: 1.221 to 2.250, P = .001) in model 2, and 1.593 (95% CI: 1.146 to 2.215, P = .006) in model 3 (Table S2, Supplemental Digital Content 3).

The association remained significant after additional adjustment for serum 25-hydroxyvitamin D (HR = 1.652, 95% CI: 1.102 to 2.477, P = .015) and physical activity (HR = 1.632, 95% CI: 1.082 to 2.462, P = .019). Survival analysis with Kaplan: Meier curves (Fig. S2, Supplemental Digital Content 4) further confirmed the findings, showing a significantly lower survival probability in sarcopenic patients (log-rank P < .001), confirming the correlation observed in the primary analysis.

4. Discussion

This study showed an association between sarcopenia and increased all-cause mortality in patients with RA. After adjusting for multiple confounders, sarcopenia was associated with a 61% higher risk of mortality, and this association remained consistent in sensitivity analyses. This finding suggests that muscle health warrants attention in this population and that early management of sarcopenia may be beneficial to long-term survival.

Our finding that sarcopenia is significantly associated with all-cause mortality in patients with RA is consistent with a large body of evidence from diverse populations. For instance, a meta-analysis by Xu et al[30] demonstrated a significant mortality association (HR = 2.00), while another by Westbury et al[8] reported a pooled HR of 2.75, underscoring the consistent relationship between muscle loss and poor outcomes. This link has been further substantiated in various specific conditions, with studies in chronic kidney disease,[31] liver cirrhosis,[32] and type 2 diabetes,[33] all identifying sarcopenia as a critical factor associated with higher mortality.

Within the specific context of RA, our results are particularly aligned with key recent studies. Consistent with findings from Xu et al[34] in a smaller RA cohort of 558 patients (adjusted HR = 1.826 to 2.112), our study in a larger cohort (n = 910) confirmed a significant association with a comparable hazard ratio (adjusted HR = 1.610). Our observed sarcopenia prevalence (19.8%) was also comparable to that reported by Shin et al[35] (20.5%). Our work also builds upon that of Bennett et al,[9] who previously highlighted the link between sarcopenia and physical disability in RA.

This is further supported by Wiegmann et al,[36] who found sarcopenia in RA diminishes quality of life, and is often exacerbated by glucocorticoid use, a key factor identified by Yamada et al.[37] Moreover, its synergistic effects with osteoporosis are known to significantly increase fracture likelihood.[20,38,39] While these previous studies established a clear link between sarcopenia and adverse physical outcomes, our longitudinal analysis extends this by demonstrating its significant association with all-cause mortality. Additionally, our subgroup analysis revealed that the strength of this association varies by patient characteristics.

Collectively, these findings suggest the potential value of integrating sarcopenia assessment into the clinical management of RA, a strategy that may aid in refining patient stratification and better informing long-term prognosis.

The association between sarcopenia and all-cause mortality in patients with RA appears to be context-dependent, varying by demographic factors such as sex and age. The heightened vulnerability observed in males, a group in whom RA is linked to more pronounced lean mass deficits,[40] may be explained by the pivotal role of testosterone. Low testosterone levels present a dual challenge for these patients: they are not only associated with an increased risk of developing RA itself,[41] but are also fundamental to maintaining muscle mass,[42] partly by mitigating muscle wasting[43] and reducing protein breakdown.[44] In addition to these sex-specific factors, the observation that this association was more pronounced in younger than in older adults is also insightful.

This may suggest that in younger individuals, sarcopenia serves as a more direct indicator of a severe underlying disease phenotype, whereas in older adults, its prognostic signal is likely attenuated by the confounding influence of natural, age-related muscle decline.[45Not reported47]

The development of sarcopenia in RA is multifactorial, driven by both the inherent inflammatory state of the disease and common therapeutic interventions. Chronic inflammation in RA is a primary driver of muscle degradation. Key inflammatory cytokines, particularly tumor necrosis factor-alpha and interleukin-6, are known to activate proteolytic pathways that lead to muscle wasting.[48] This inflammatory environment may also alter macrophage polarization towards a pro-catabolic M1 phenotype,[49,50] while concurrent metabolic disruptions, including altered lipid metabolism and impaired protein synthesis, further contribute to the loss of muscle mass.[51,52] Compounding these disease-driven processes, glucocorticoid (GC) therapy, a common component of RA management, significantly exacerbates muscle atrophy.

GCs are known to directly interfere with muscle health by reducing both mass and function,[53] with higher doses linked to a greater likelihood of muscle loss.[37] Mechanistically, GCs promote muscle degradation by upregulating key catabolic regulators like myostatin and atrogenes, such as atrogin-1 and MuRF-1.[54] The deleterious impact of these therapies is often amplified by vitamin D deficiency, a common issue in patients undergoing GC treatment.[55] These findings, therefore, suggest that sarcopenia may reflect an underlying systemic burden that is also associated with all-cause mortality in patients with RA.

This study has several strengths. First, we used the NHANES database, which provided a large sample size and established a solid foundation for our analysis. Second, our Cox regression models controlled for a wide range of demographic, clinical, and lifestyle indicators, which supports the robustness of the results. Additionally, subgroup and sensitivity analyses were conducted to further validate our findings. However, this study also has several limitations. To begin with, the reliance on self-reported data, such as the RA diagnosis, is a potential source of information bias, even if the method has been previously validated.

The assessment of sarcopenia using body composition data could also be influenced by potential measurement errors. Furthermore, our analysis did not account for several important clinical variables, such as disease activity, specific treatment regimens, or nutritional status, and the absence of these data introduces the possibility of residual confounding. Lastly, the retrospective nature of the data limited our ability to control for dynamic changes in disease progression over time. Therefore, the long-term relationship between sarcopenia and mortality in patients with RA needs to be further investigated with prospective studies.

5. Conclusion

The present longitudinal analysis identifies an association between sarcopenia and an elevated risk of all-cause mortality among patients with RA. This finding underscores the clinical relevance of monitoring skeletal muscle health in this population. Furthermore, the observed association provides a rationale for future research to evaluate the relationship between muscle status and long-term outcomes.

Acknowledgments

We gratefully acknowledge the invaluable contributions of all NHANES participants to this research.

Author contributions

Data curation: Xiaodong Zhang, Hua Liu.

Formal analysis: Xiaodong Zhang, Hua Liu.

Investigation: Xiaodong Zhang, Hua Liu.

Methodology: Xiaodong Zhang, Hua Liu.

Visualization: Xiaodong Zhang.

Writing: original draft: Xiaodong Zhang, Hua Liu.

Writing: review & editing: Tianzuo Lan, Xin Cai.

Supplement file at the original source: open the original paper. This file is not included in this text import.
Supplement file at the original source: open the original paper. This file is not included in this text import.
Supplement file at the original source: open the original paper. This file is not included in this text import.
Supplement file at the original source: open the original paper. This file is not included in this text import.

Abbreviations:

ASM

appendicular skeletal muscle mass

BMI

body mass index

CI

confidence interval

DXA

dual-energy x-ray absorptiometry

GC

glucocorticoid

HbA1c

hemoglobin A1c

HR

hazard ratio

MET

metabolic equivalent of task

NHANES

National Health and Nutrition Examination Survey

PIR

poverty-to-income ratio

RA

rheumatoid arthritis

The authors have no funding and conflicts of interest to declare.

All data generated or analyzed during this study are included in this published article (and its supplementary information files).

Supplemental Digital Content is available in the online version of this article (http://dx.doi.org/10.1097/MD.0000000000050000).

How to cite this article: Zhang X, Liu H, Lan T, Cai X. Sarcopenia, an independent predictor for all-cause mortality in rheumatoid arthritis: Insights from the NHANES database. Medicine 2026;105:31(e50000).

References

[1] Sparks JA . Rheumatoid arthritis. Ann Intern Med . 2019 ;170 :ITC1Not reportedITC16 . 30596879 10.7326/AITC201901010
[2] Lacaille D Avina-Zubieta JA Sayre EC Abrahamowicz M . Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap. Ann Rheum Dis . 2017 ;76 :1057Not reported63 . 28031164 10.1136/annrheumdis-2016-209562 PMC5526676
[3] Widdifield J Paterson JM Huang A Bernatsky S . Causes of death in rheumatoid arthritis: how do they compare to the general population? Arthritis Care Res . 2018 ;70 :1748Not reported55 . 10.1002/acr.23548 29512334
[4] Taylor-Gjevre RM Nair BV Jin S Quail J . Higher mortality rates associated with rheumatoid arthritis in Saskatchewan, Canada, 2001-2019. Can J Public Health . 2021 ;112 :722Not reported32 . 33595819 10.17269/s41997-021-00476-w PMC8225749
[5] Black RJ Lester S Tieu J . Mortality estimates and excess mortality in rheumatoid arthritis. Rheumatology (Oxford, England) . 2023 ;62 :3576Not reported83 . 36919770 10.1093/rheumatology/kead106 PMC10629787
[6] Abasolo L Ivorra-Cortes J Leon L Jover JA Fernandez-Gutierrez B Rodriguez-Rodriguez L . Influence of demographic and clinical factors on the mortality rate of a rheumatoid arthritis cohort: a 20-year survival study. Semin Arthritis Rheum . 2016 ;45 :533Not reported8 . 26639031 10.1016/j.semarthrit.2015.10.016
[7] Cruz-Jentoft AJ Sayer AA . Sarcopenia. Lancet . 2019 ;393 :2636Not reported46 . 31171417 10.1016/S0140-6736(19)31138-9
[8] Westbury LD Beaudart C Bruyere O ; International Musculoskeletal Ageing Network. Recent sarcopenia definitions-prevalence, agreement and mortality associations among men: findings from population-based cohorts. J Cachexia Sarcopenia Muscle . 2023 ;14 :565Not reported75 . 36604970 10.1002/jcsm.13160 PMC9891989
[9] Bennett JL Pratt AG Dodds R Sayer AA Isaacs JD . Rheumatoid sarcopenia: loss of skeletal muscle strength and mass in rheumatoid arthritis. Nat Rev Rheumatol . 2023 ;19 :239Not reported51 . 36801919 10.1038/s41584-023-00921-9
[10] Jung HN Jung CH Hwang YC . Sarcopenia in youth. Metabolism . 2023 ;144 :155557 . 37080353 10.1016/j.metabol.2023.155557
[11] Tekgoz E Colak S Ozalp Ates FS Sonaeren I Yilmaz S Cinar M . Sarcopenia in rheumatoid arthritis: is it a common manifestation? Int J Rheum Dis . 2020 ;23 :1685Not reported91 . 32979041 10.1111/1756-185X.13976
[12] Moschou D Krikelis M Georgakopoulos C . Sarcopenia in rheumatoid arthritis. a narrative review. J Frailty Sarcopenia Falls . 2023 ;8 :44Not reported52 . 36873824 10.22540/JFSF-08-044 PMC9975974
[13] Li TH Chang YS Liu CW . The prevalence and risk factors of sarcopenia in rheumatoid arthritis patients: a systematic review and meta-regression analysis. Semin Arthritis Rheum . 2021 ;51 :236Not reported45 . 33385864 10.1016/j.semarthrit.2020.10.002
[14] Cano-Garcia L Manrique-Arija S Dominguez-Quesada C . Sarcopenia and nutrition in elderly rheumatoid arthritis patients: a cross-sectional study to determine prevalence and risk factors. Nutrients . 2023 ;15 :2440 . 37299407 10.3390/nu15112440 PMC10255254
[15] Bai T Fang F Li F Ren Y Hu J Cao J . Sarcopenia is associated with hypertension in older adults: a systematic review and meta-analysis. BMC Geriatr . 2020 ;20 :279 . 32762638 10.1186/s12877-020-01672-y PMC7409686
[16] Otten L Stobaus N Franz K . Impact of sarcopenia on 1-year mortality in older patients with cancer. Age Ageing . 2019 ;48 :413Not reported8 . 30608508 10.1093/ageing/afy212
[17] Kim D Wijarnpreecha K Sandhu KK Cholankeril G Ahmed A . Sarcopenia in nonalcoholic fatty liver disease and all-cause and cause-specific mortality in the United States. Liver Int . 2021 ;41 :1832Not reported40 . 33641244 10.1111/liv.14852
[18] Zhao Q Yin Y Deng Y . Metabolic associated fatty liver disease and sarcopenia additively increase mortality: a real-world study. Nutr Diabetes . 2023 ;13 :21 . 37968264 10.1038/s41387-023-00250-6 PMC10651884
[19] Dao T Kirk B Phu S Vogrin S Duque G . Prevalence of sarcopenia and its association with antirheumatic drugs in middle-aged and older adults with rheumatoid arthritis: a systematic review and meta-analysis. Calcif Tissue Int . 2021 ;109 :475Not reported89 . 34132852 10.1007/s00223-021-00873-w
[20] Lian L Wang JX Xu YC Zong HX Teng YZ Xu SQ . Sarcopenia may be a risk factor for osteoporosis in Chinese patients with rheumatoid arthritis. Int J Gen Med . 2022 ;15 :2075Not reported85 . 35237070 10.2147/IJGM.S349435 PMC8882659
[21] Zhang M Xu S Zong H . Effect of sarcopenia and poor balance on vertebral spinal osteoporotic fracture in female rheumatoid arthritis. Sci Rep . 2022 ;12 :9477 . 35676311 10.1038/s41598-022-13339-2 PMC9177606
[22] Flegal KM Kruszon-Moran D Carroll MD Fryar CD Ogden CL . Trends in obesity among adults in the United States, 2005 to 2014. JAMA . 2016 ;315 :2284Not reported91 . 27272580 10.1001/jama.2016.6458 PMC11197437
[23] Liu B Wang J Li YY Li KP Zhang Q . The association between systemic immune-inflammation index and rheumatoid arthritis: evidence from NHANES 1999-2018. Arthritis Res Ther . 2023 ;25 :34 . 36871051 10.1186/s13075-023-03018-6 PMC9985219
[24] Che QC Jia Q Zhang XY Sun SN Zhang XJ Shu Q . A prospective study of the association between serum klotho and mortality among adults with rheumatoid arthritis in the USA. Arthritis Res Ther . 2023 ;25 :149 . 37587536 10.1186/s13075-023-03137-0 PMC10428634
[25] Studenski SA Peters KW Alley DE . The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci . 2014 ;69 :547Not reported58 . 24737557 10.1093/gerona/glu010 PMC3991146
[26] Harring M Golabi P Paik JM . Sarcopenia among patients with nonalcoholic fatty liver disease (NAFLD) is associated with advanced fibrosis. Clin Gastroenterol Hepatol . 2023 ;21 :2876Not reported88.e5 . 36848980 10.1016/j.cgh.2023.02.013
[27] Yang J Liu C Zhao S . The association between the triglyceride-glucose index and sarcopenia: data from the NHANES 2011-2018. Lipids Health Dis . 2024 ;23 :219 . 39030624 10.1186/s12944-024-02201-1 PMC11264742
[28] Zhang X Ma N Lin Q . Body roundness index and all-cause mortality among US adults. JAMA Netw Open . 2024 ;7 :e2415051 . 38837158 10.1001/jamanetworkopen.2024.15051 PMC11154161
[29] Cheng TD Ferderber C Kinder B Wei YJ . Trends in dietary vitamin a intake among US adults by race and ethnicity, 2003-2018. JAMA . 2023 ;329 :1026Not reported9 . 36976287 10.1001/jama.2023.0636 PMC10051065
[30] Xu J Wan CS Ktoris K Reijnierse EM Maier AB . Sarcopenia is associated with mortality in adults: a systematic review and meta-analysis. Gerontology . 2022 ;68 :361Not reported76 . 34315158 10.1159/000517099
[31] Pereira RA Cordeiro AC Avesani CM . Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association with mortality. Nephrol Dialysis Transpl . 2015 ;30 :1718Not reported25 . 10.1093/ndt/gfv133 25999376
[32] Tantai X Liu Y Yeo YH . Effect of sarcopenia on survival in patients with cirrhosis: a meta-analysis. J Hepatol . 2022 ;76 :588Not reported99 . 34785325 10.1016/j.jhep.2021.11.006
[33] Takahashi F Hashimoto Y Kaji A . Sarcopenia is associated with a risk of mortality in people with type 2 diabetes mellitus. Front Endocrinol . 2021 ;12 :783363 . 10.3389/fendo.2021.783363 PMC8632440 34858351
[34] Xu Q Du X . Sarcopenia and all-cause mortality in US adults with and without rheumatoid arthritis [abstract]. Arthritis Rheumatol . 2023 ;75 (suppl 9 ):Abstract 0976 .
[35] Shin A Choi SR Han M . Association between sarcopenia defined as low lean mass by dual-energy X-ray absorptiometry and comorbidities of rheumatoid arthritis: results of a nationwide cross-sectional health examination. Semin Arthritis Rheum . 2022 ;57 :152090 . 36099743 10.1016/j.semarthrit.2022.152090
[36] Wiegmann S Armbrecht G Borucki D . Association between sarcopenia, physical performance and falls in patients with rheumatoid arthritis: a 1-year prospective study. BMC Musculoskelet Disord . 2021 ;22 :885 . 34663280 10.1186/s12891-021-04605-x PMC8524907
[37] Yamada Y Tada M Mandai K Hidaka N Inui K Nakamura H . Glucocorticoid use is an independent risk factor for developing sarcopenia in patients with rheumatoid arthritis: from the CHIKARA study. Clin Rheumatol . 2020 ;39 :1757Not reported64 . 31938882 10.1007/s10067-020-04929-4
[38] Chu YR Xu SQ Wang JX . Synergy of sarcopenia and vitamin D deficiency in vertebral osteoporotic fractures in rheumatoid arthritis. Clin Rheumatol . 2022 ;41 :1979Not reported87 . 35253099 10.1007/s10067-022-06125-y
[39] Tong JJ Xu SQ Wang JX . Interactive effect of sarcopenia and falls on vertebral osteoporotic fracture in patients with rheumatoid arthritis. Arch Osteoporos . 2021 ;16 :145 . 34601644 10.1007/s11657-021-01017-1
[40] Baker JF Long J Ibrahim S Leonard MB Katz P . Are men at greater risk of lean mass deficits in rheumatoid arthritis? Arthritis Care Res . 2015 ;67 :112Not reported9 . 10.1002/acr.22396 PMC4280305 25048740
[41] Wen P Wang Y Yang M . Sex hormone imbalance and rheumatoid arthritis in American men: a cross-sectional analysis from NHANES 2011-2016. Front Immunol . 2024 ;15 :1501257 . 39759528 10.3389/fimmu.2024.1501257 PMC11695343
[42] Auyeung TW Lee JS Kwok T . Testosterone but not estradiol level is positively related to muscle strength and physical performance independent of muscle mass: a cross-sectional study in 1489 older men. Eur J Endocrinol . 2011 ;164 :811Not reported7 . 21346095 10.1530/EJE-10-0952
[43] Atkinson RA Srinivas-Shankar U Roberts SA . Effects of testosterone on skeletal muscle architecture in intermediate-frail and frail elderly men. J Gerontol A Biol Sci Med Sci . 2010 ;65 :1215Not reported9 . 20601412 10.1093/gerona/glq118
[44] Kruse R Petersson SJ Christensen LL . Effect of long-term testosterone therapy on molecular regulators of skeletal muscle mass and fibre-type distribution in aging men with subnormal testosterone. Metabolism . 2020 ;112 :154347 . 32853647 10.1016/j.metabol.2020.154347
[45] Santo RCE Fernandes KZ Lora PS Filippin LI Xavier RM . Prevalence of rheumatoid cachexia in rheumatoid arthritis: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle . 2018 ;9 :816Not reported25 . 30133186 10.1002/jcsm.12320 PMC6204596
[46] Do Espírito Santo RC de Moraes DN Dória LD . Longitudinal impact of sarcopenia and its components on falls, fractures, and mortality in rheumatoid arthritis: a six-year study. BMC Rheumatol . 2025 ;9 :142 . 41299632 10.1186/s41927-025-00593-w PMC12659329
[47] Jia P Lin J Zou Y . The characteristic of muscle function for sarcopenia in patients with rheumatoid arthritis: a large-scale real-world cross-sectional study. Medicina (Kaunas, Lithuania) . 2025 ;61 :551 . 40282842 10.3390/medicina61040551 PMC12028369
[48] Noack M Miossec P . Selected cytokine pathways in rheumatoid arthritis. Semin Immunopathol . 2017 ;39 :365Not reported83 . 28213794 10.1007/s00281-017-0619-z
[49] Sciorati C Rigamonti E Manfredi AA Rovere-Querini P . Cell death, clearance and immunity in the skeletal muscle. Cell Death Differ . 2016 ;23 :927Not reported37 . 26868912 10.1038/cdd.2015.171 PMC4987728
[50] Babaeijandaghi F Paiero A Long R . TNFα and IFNγ cooperate for efficient pro: to anti-inflammatory transition of macrophages during muscle regeneration. Proc Natl Acad Sci USA . 2022 ;119 :e2209976119 . 36279473 10.1073/pnas.2209976119 PMC9636974
[51] Hardee JP Counts BR Gao S . Inflammatory signalling regulates eccentric contraction-induced protein synthesis in cachectic skeletal muscle. J Cachexia Sarcopenia Muscle . 2018 ;9 :369Not reported83 . 29215198 10.1002/jcsm.12271 PMC5879978
[52] Chimenti MS Triggianese P Conigliaro P Candi E Melino G Perricone R . The interplay between inflammation and metabolism in rheumatoid arthritis. Cell Death Dis . 2015 ;6 :e1887 . 26379192 10.1038/cddis.2015.246 PMC4650442
[53] Prabakaran AD Mcfarland K Miz K . Intermittent glucocorticoid treatment improves muscle metabolism via the PGC1alpha/Lipin1 axis in an aging-related sarcopenia model. J Clin Invest . 2024 ;134 :e177427 . 38702076 10.1172/JCI177427 PMC11142738
[54] Hong Y Lee JH Jeong KW Choi CS Jun HS . Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy. J Cachexia Sarcopenia Muscle . 2019 ;10 :903Not reported18 . 31020810 10.1002/jcsm.12434 PMC6711418
[55] Li WJ Wang XL Chu YR Wang JX Xu SQ . Association of sarcopenia and vitamin D deficiency with glucocorticoid-induced osteoporosis in Chinese patients with rheumatoid arthritis. Clin Rheumatol . 2024 ;43 :15Not reported22 . 37831335 10.1007/s10067-023-06784-5
Publication and source details

Original title: Sarcopenia, an independent predictor for all-cause mortality in rheumatoid arthritis: Insights from the NHANES database

Xiaodong Zhang; Hua Liu; Tianzuo Lan; Xin Cai

Medicine · 2026

* Correspondence: Xin Cai, Department of Rheumatology and Immunology, The First People’s Hospital of Guiyang, No. 97 Bo’ai Road, Nanming District, Guiyang 550002, Guizhou, China (e-mail: sylvan25@163.com).Copyright © 2026 the Author(s). Published by Wolters Kluwer Health, LLC.2026https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:11:33.082909+00:00

DOI: 10.1097/md.0000000000050000 · PMC13433025